Show simple item record

dc.contributor.authorTam, CS
dc.contributor.authorOpat, S
dc.contributor.authorSimpson, D
dc.contributor.authorCull, G
dc.contributor.authorMunoz, J
dc.contributor.authorPhillips, TJ
dc.contributor.authorKim, WS
dc.contributor.authorRule, S
dc.contributor.authorAtwal, SK
dc.contributor.authorWei, R
dc.contributor.authorNovotny, W
dc.contributor.authorHuang, J
dc.contributor.authorWang, M
dc.contributor.authorTrotman, J
dc.date.accessioned2022-03-07T14:07:02Z
dc.date.issued2021-06-22
dc.identifier.issn2473-9529
dc.identifier.issn2473-9537
dc.identifier.urihttp://hdl.handle.net/10026.1/18906
dc.description.abstract

<jats:title>Abstract</jats:title> <jats:p>Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase 1/2 study in patients with various B-cell malignancies. In the subgroup of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), zanubrutinib was administered as 160 mg twice daily (n = 14), 320 mg once daily (n = 18), or ≤160 mg total dose (n = 5). Herein, we report results for patients receiving a total daily dose of 320 mg (N = 32). Median study follow-up was 18.8 months. Eighteen patients discontinued treatment, 10 because of progressive disease and 8 because of adverse events (AEs); 1 AE (peripheral edema) was considered to be related to zanubrutinib treatment. The most common AEs were diarrhea (43.8%), contusion (37.5%), constipation (31.3%), and upper respiratory tract infection (31.3%). Infection was the most commonly reported AE of interest (18.8% of patients experienced grade ≥3 infection). At least 1 AE of grade ≥3 was reported in 59.4% of patients; grade ≥3 AEs that were reported in &amp;gt;2 patients were anemia (12.5%), pneumonia (9.4%), and myalgia (9.4%). Overall response rate was 84%, with 25% achieving a complete response. Median duration of response was 18.5 months. Median progression-free survival (PFS) was 21.1 months. Zanubrutinib was well tolerated and demonstrated activity in patients with R/R MCL. The trial is registered at www.clinicaltrials.gov as #NCT02343120.</jats:p>

dc.format.extent2577-2585
dc.format.mediumPrint
dc.languageen
dc.language.isoen
dc.publisherAmerican Society of Hematology
dc.subjectAdult
dc.subjectHumans
dc.subjectLymphoma, Mantle-Cell
dc.subjectPiperidines
dc.subjectPyrazoles
dc.subjectPyrimidines
dc.titleZanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
dc.typejournal-article
dc.typeArticle
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/34152395
plymouth.issue12
plymouth.volume5
plymouth.publisher-urlhttp://dx.doi.org/10.1182/bloodadvances.2020004074
plymouth.publication-statusPublished
plymouth.journalBlood Advances
dc.identifier.doi10.1182/bloodadvances.2020004074
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeUnited States
dcterms.dateAccepted2021-04-08
dc.rights.embargodate2022-3-8
dc.identifier.eissn2473-9537
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1182/bloodadvances.2020004074
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-06-22
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV